HeartWare’s still chasing PMA, more study results on the way

Heartware's still chasing PMA for destination therapy, more study results on the way

Framingham, Mass.-based medical device company HeartWare International (NSDQ:HTWR) hopes its newly approved cohort of heart pump clinical trial patients will help quell concerns about "neurological events" associated with its implant in earlier studies.

North Carolina cardiologist Dr. Joseph Rogers, a principal investigator for HeartWare’s ENDURANCE trial, told reporters that he plans to submit the latest clinical findings for presentation at the 2014 American Heart Assn. meeting or the subsequent meeting of the American College of Cardiology, including both the original patient cohort as well as the supplemental cohort that is receiving blood pressure management in addition to the implantable heart pump.

The ENDURANCE trial hit a speed-bump early on when researchers noted an unexpectedly high rate of ischemic and hemorrhagic strokes in HeartWare patients (6.7% and 5.1% respectively), as compared to a control pump (4.3% and 0%, respectively). Those findings prompted the FDA to take a peek at HeartWare’s interim results, and the company eventually targeted blood pressure management as a potential avenue for stemming further adverse events, TheHeart.org reported.

Asking for those interim results was "a very unusual request from the FDA," Rogers told the news source, "but it is what it is."

"There was a question of whether the adverse-event rate for neurological events was higher with HeartWare, so that’s what prompted the company to go back into the data set and identify factors that may be associated with that, and one of the factors that came out was high blood pressure," he added.

In June 2013 the FDA granted HeartWare conditional approval for another 360-patient cohort, expanding the original ENDURANCE trial to evaluate the effect of closer blood pressure monitoring on neurological events. At the time, HeartWare said that the new study aimed to "confirm observations from Endurance that sites adhering to more regular monitoring and management of patient blood pressure witnessed a notably lower incidence of neurological events."

Rogers hopes to use data from both the original and the expanded cohort of patients to draw conclusions about patient outcomes with the heart pump as a destination therapy, but combining the data could mean diluting important warnings.

"This field is still in its relative youth, and there are things we don’t know about the pumps," he told The Heart. "We were assuming that those 2 pumps we were testing in ENDURANCE are the same, and they are not, they are very different pumps. So it may be that BP management is more important with one than the other."

HTWR shares were flat at $80.21 as of about 12:50 p.m. today, still trending downward overall since the company released a mixed Q2 earnings report earlier this month. The company came under pressure after it missed Wall Street’s loss-per-share forecast on lower-than-expected U.S. sales of its implantable heart pump during the 2nd quarter.

RSS From Medical Design & Outsourcing

  • GlobTek presents its latest level VI AC/DC adapter and connverter
    T-43086-WWVV-X.X-Q Model is an addition to GlobTek’s Level VI compliant GT-43086 family and represents GlobTek’s 6 Watt wall plug-in series of AC/DC adapters (power supplies and chargers) with International Interchangeable blades. GlobTek’s changeable input blade system with individual field replaceable input plugs, including: North America and Japan NEMA 1-15P, Australian, UK BS 1363, European CEE […]
  • Sanmina’s familiarity with FDA gets skin treatment product to market fast
    The medical market for cosmetic devices is booming. However, quickly launching new products to meet demand is becoming more challenging because device manufactures face increased regulatory scrutiny. To help meet regulatory requirements, aesthetic and other medical-device OEMs are partnering with electronics manufacturing services (EMS) companies that also offer expertise with the FDA filings necessary to […]
  • Fluid connectors and quick disconnects for IVD equipment from CPC
    Colder Products Company (CPC) offers thousands of tubing connectors, quick disconnects and fittings for smart fluid handling in IVD and analytical equipment. Non-spill connectors speed testing throughput by eliminating drips, preventing air inclusion and increasing operator safety. Panel mount connectors can be added to existing equipment or bottle caps to provide secure, leak-free connections. Puncture […]
  • 310 Watt desktop medical power supply meets efficiency level VI requirements
    Power Partners releases a new 310 Watt medical grade desktop power supply from their PEAMD Series of AC and DC adapters. The 310 Watt unit is packed for ideal performance inside a compact case measuring 7.8 x 4 x 2 in. with a weight of only 3 lbs. The PEAMD310 Series is approved to the latest […]
  • Saelig introduces Multiple Instrument System MIS4 universal test system
    Saelig Company has introduced the ABI Electronics’ Multiple Instrument Station MIS4, an all-in-one testing tool that provides all commonly required test instruments in one compact programmable hardware module, mounted in a compact case or installed in a PC-drive bay. Controlled by ABI’s sophisticated SYSTEM 8 Ultimate PC software with a simple yet programmable operator interface, […]
  • AssurX announces document management software update for small to mid-size companies in FDA regulated industries
    AssurX, an enterprise quality management, risk and regulatory compliance solution provider, announces the release of the latest update to their AssurX document management software. The document management solution provides a cost-effective solution for small to medium sized companies faced with streamlined operations and is fully compliant for FDA regulated industries. Ideal solution for small to […]
  • Saelig presents new Amplicon Impact-R 1100F series computer
    Saelig Company announces the Amplicon Impact-R 1100F series, a fanless system powered by the Intel ATOM D2550 processor. Configured with a high performance 2.5 in. MLC Solid State Drive (SSD), the Impact-R 1100F series is a silent controller system. With options for multiple serial communication ports, the Impact-R 1100F can offer up seven DB9 connections […]
  • Gerresheimer to acquire Centor
    Gerresheimer AG, a partner to the global pharmacy and healthcare industry, will further extend its pharmaceutical packaging business with the acquisition of Centor. Gerresheimer has reached an agreement with Nemera Development S.A. to acquire 100% of the share capital of Centor US Holding. “Centor is the highly profitable market leader for plastic vials and closures in […]
  • Methods Machine Tools presents the new Nakamura-Tome NTRX-300
    Methods Machine Tools, a developer of precision machine tools and automation, has introduced the new Nakamura-Tome NTRX-300, a multitasking turning center featuring complete parts machining in one operation, with a built-in load and unload automation system and advanced operator recognition management software. The NTRX-300 features true opposing twin spindles: an 8 in. A2-6 25 HP or […]
  • MSC Apex Diamond Python and Smart Midsurface speeds modeling to validation
    MSC Software announced a new release of MSC Apex, the company’s award-winning next generation Computer Aided Engineering (CAE) platform. The MSC Apex Diamond Python release introduces: · The fourth release of MSC Apex Modeler is a CAE Specific direct modeling and meshing solution that streamlines CAD clean-up, simplification and meshing workflow. New in this release is […]
  • Quality Metrics: FDA’s plan for a key set of measurements to help ensure manufacturers are producing quality medications
    Editor’s Note: This article is written by Ashley Boam and Mary Malarkey from the “FDA Voice” blog. Boam is an FDA’s acting Director of the Office of Policy for Pharmaceutical Quality, the Office of Pharmaceutical Quality and the Center for Drug Evaluation and Research. Malarkey is an FDA’s Director if the Office of Compliance and Biologics Quality […]

Leave a Reply